Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 16/20 | 0.99 |
| ▸ | BCR known ✓ | P11274 | 8/20 | 0.99 |
| ▸ | KIT | P10721 | 11/20 | 0.99 |
| ▸ | LDLR | P01130 | 8/20 | 0.99 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 0.99 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.99 |
| ▸ | LCK | P06239 | 4/20 | 0.99 |
| ▸ | LYN | P07948 | 4/20 | 0.99 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.99 |
| ▸ | FLT3 | P36888 | 4/20 | 0.99 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.99 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.99 |
| ▸ | SRC | P12931 | 2/20 | 0.99 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.99 |
| ▸ | CA12 | O43570 | 1/20 | 0.99 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.99 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.99 |
| ▸ | STK10 | O94804 | 1/20 | 0.99 |
| ▸ | CA1 | P00915 | 1/20 | 0.99 |
| ▸ | CA2 | P00918 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilotinib SCHEMBL1565706 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL31005052 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1459790 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28656586 | 1.00 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL235245 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL18095566 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL2223849 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1460791 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL29392981 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28663798 | 0.99 | ABL1 (0.97) | ABL1KITBCRLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 581 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115192-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| EP-4355306-B1 | GRANULATE COMPOSITION COMPRISING NILOTINIB | HELM PHARMACEUTICALS GMBH (DE) | 2026-01-21 | — | — | EP | claimed |
| CN-119504709-A | Spherical crystal of nilotinib hydrochloride medicinal crystal form B and preparation method thereof | 四川弘远药业有限公司 | 2025-02-25 | — | — | CN | claimed |
| US-20250032491-A1 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | FLEX PHARMA, LLC | 2025-01-30 | — | — | US | claimed |
| US-20240316044-A1 | GRANULATE COMPOSITION COMPRISING NILOTINIB | HELM AG (DE) | 2024-09-26 | — | — | US | claimed |
| US-12065426-B2 | Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same | LAURUS LABS LIMITED (IN) | 2024-08-20 | — | — | US | claimed |
| US-12053471-B2 | Amorphous nilotinib microparticles and uses thereof | NANOCOPOEIA, LLC (US) | 2024-08-06 | — | — | US | claimed |
| US-11998548-B2 | Amorphous nilotinib microparticles and uses thereof | NANOCOPOEIA, LLC (US) | 2024-06-04 | — | — | US | claimed |
| EP-4355306-A1 | GRANULATE COMPOSITION COMPRISING NILOTINIB | Helm AG (DE) | 2024-04-24 | — | — | EP | claimed |
| CN-110785187-B | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| US-20130245052-A1 | NOVEL POLYMORPH OF NILOTINIB HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2013-09-19 | — | — | US | claimed |
| US-8343984-B2 | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | claimed |
| WO-2012164578-A1 | COMPOSITIONS AND METHODS FOR PREPARING IMMEDIATE RELEASE FORMULATIONS OF NILOTINIB | HETERO RESEARCH FOUNDATION (IN) | 2012-12-06 | — | — | WO | claimed |
| WO-2012070062-A2 | NOVEL POLYMORPH OF NILOTINIB HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2012-05-31 | — | — | WO | claimed |
| CN-102453024-A | Nilotinib hydrochloride crystal form and preparation method thereof | ZHEJIANG JIUZHOU PHARM CO LTD | 2012-05-16 | — | — | CN | claimed |
| US-8163904-B2 | Prepared by reacting free base with an acid in methanol under a nitrogen atmosphere; use in treating a disease which responds to an inhibition of protein kinase activity | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | claimed |
| WO-2011086541-A1 | NOVEL POLYMORPH OF NILOTINIB MONOHYDROCHLORIDE MONOHYDRATE | GENERICS [UK] LIMITED (GB) | 2011-07-21 | — | — | WO | claimed |
| WO-2011033307-A1 | NILOTINIB DIHYDROCHLORIDE SALT | GENERICS [UK] LIMITED (GB) | 2011-03-24 | — | — | WO | claimed |
| CN-101516344-A | Pharmaceutical composition comprising nilotinib or a salt thereof | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | claimed |
| CN-101228150-A | Crystalline forms of 4-methyl-N- [ 3- (4-methyl-imidazol-1-yl) -5-trifluoromethyl-phenyl ] -3- (4-pyridin-3-yl-pyrimidin-2-ylamino) -benzamide | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316044-A1 | GRANULATE COMPOSITION COMPRISING NILOTINIB | ABL1, GRN, TP53 | ABL1 1/4885BCR 111/4885KIT 576/4885 |
| US-20260115192-A1 | PHARMACEUTICAL COMPOSITIONS | ABL1, FLT3, BCR | ABL1 1/4885BCR 3/4885KIT 56/4885 |
| US-20130245052-A1 | NOVEL POLYMORPH OF NILOTINIB HYDROCHLORIDE | ABL1, TP53, NRAS | ABL1 1/4885BCR 127/4885KIT 477/4885 |
| US-20250032491-A1 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | ABL1, CDKN1A, CDK2 | ABL1 1/4885BCR 173/4885KIT 246/4885 |
| US-12053471-B2 | Amorphous nilotinib microparticles and uses thereof | ABL1, CDKN1A, CDK2 | ABL1 1/4885BCR 173/4885KIT 246/4885 |
| US-12065426-B2 | Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same | ABL1, LCK, FYN | ABL1 1/4885BCR 13/4885KIT 229/4885 |
| US-11998548-B2 | Amorphous nilotinib microparticles and uses thereof | ABL1, CDKN1A, CDK2 | ABL1 1/4885BCR 173/4885KIT 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.